Scientists are excitedly focused on retatrutide, a novel treatment from Eli Lilly, as a significant advance in physique loss . Distinct from many existing approaches, retatrutide is a dual -action compound targeting both GLP-1 and GIP, chemicals that influence hunger and blood glucose control . Ini